Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

Abstract

BACKGROUND Sitagliptin phosphate, the first dipeptidyl peptidase 4 (DPP-4) inhibitor, provides a new treatment option for patients with type 2 diabetes. OBJECTIVE The purpose of this article is to review the pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, adverse effects, and cost of sitagliptin in adults with type 2 diabetes… (More)
DOI: 10.1016/j.clinthera.2007.12.034

Topics

Cite this paper

@article{Zerilli2007SitagliptinPA, title={Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.}, author={Tina Zerilli and Eunice Y Pyon}, journal={Clinical therapeutics}, year={2007}, volume={29 12}, pages={2614-34} }